INFILTRATING BLADDER UROTHELIAL CARCINOMA, PLASMACYTOID VARIANT
Clinical trials for INFILTRATING BLADDER UROTHELIAL CARCINOMA, PLASMACYTOID VARIANT explained in plain language.
Never miss a new study
Get alerted when new INFILTRATING BLADDER UROTHELIAL CARCINOMA, PLASMACYTOID VARIANT trials appear
Sign up with your email to follow new studies for INFILTRATING BLADDER UROTHELIAL CARCINOMA, PLASMACYTOID VARIANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo shows promise for tough bladder cancer
Disease control OngoingThis early-phase study tested two immunotherapy drugs (durvalumab and tremelimumab) given before surgery to people with a serious type of bladder cancer that cannot be treated with standard chemotherapy. The main goal was to check safety and side effects. Researchers also looked …
Matched conditions: INFILTRATING BLADDER UROTHELIAL CARCINOMA, PLASMACYTOID VARIANT
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New drug combo targets Hard-to-Treat bladder cancer
Disease control OngoingThis study tests a combination of two drugs, pemetrexed and avelumab, in people with a specific type of advanced bladder cancer that lacks a protein called MTAP. The goal is to see if this treatment can shrink or control the cancer. About 18 participants who have already tried ch…
Matched conditions: INFILTRATING BLADDER UROTHELIAL CARCINOMA, PLASMACYTOID VARIANT
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC